Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. (Q46485560)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

title

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

K G Smith

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Herman Waldmann

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

10

Geoff Hale

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

J Andrew Bradley

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Peter J Friend

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

John Firth

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Craig J Taylor

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Sathia Thiru

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Neville V Jamieson

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Roy Calne

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

John R Bradley

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

language of work or name

English

0 references

publication date

1 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Transplantation

11 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

1347-1353

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15888040%20AND%20SRC:MED&resulttype=core&format=json

Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders

11 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.00822.X

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.00822.X

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.00822.X

Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.00822.X

Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.00822.X

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.00822.X

Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.00822.X

The use of Campath-1H as induction therapy in renal transplantation: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.00822.X

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.00822.X

Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.00822.X